A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs IFX 1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SHINE
- Sponsors InflaRx
- 04 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2018 According to an InflaRx media release, company today announced that the first patient has been enrolled in this study.
- 08 Mar 2018 Status changed from planning to recruiting, according to an InflaRx media release.